Eli Lilly and Company Buyback
OLI recorded this information on 12/17/2012
Eli Lilly and Company
The Lilly board of directors also authorized the initiation of a new $1.5 billion share repurchase program, which the company anticipates completing in 2013. The company recently completed a $3.0 billion share repurchase program that was started in 2000. All purchases under the new $1.5 billion share repurchase program will be made on the open market at prevailing prices. Purchases will be made over a period to be determined by management of the company. Shares acquired will be retired.
Eli Lilly and Company is engaged in discovering, developing, manufacturing, and marketing products in two business segments: human pharmaceutical products; and animal health products. Co.'s human pharmaceutical products include: cardiovascular, endocrinology, immunology, neuroscience and oncology products. Co.'s animal health products are comprised of products for animals, among others, which include Clynav, a vaccine to control pancreas disease in salmon; Coban®, Maxiban®, and Monteban®, anticoccidial agents for use in poultry; as well as products for companion animals, which include Comfortis®, a chewable tablet that kills fleas and prevents flea infestations on dogs.
Eli Lilly SEC Filing Email Alerts Service
Open the LLY Page at The Online Investor »
Strong Buy (3.78 out of 4)
(ranked higher than approx. 73% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite